Translation Control Therapeutics
See the light of Protein Translation
New approach
New technology
New drugs

AnimaBiotech

Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation

Translation Control Discovery Platform

Breakthrough Biology

Cloud Architecture

Proprietary Analysis

Translation Control Platform
We purified and fluorescently labeled all 48 types of human tRNA
Using FRET signals from signature tRNA pair(s) of the target protein, we visualize and monitor its translation
Using all 48 tRNA pairs together, we can monitor the cell’s complete protein translation activity
Using the signature pairs for its group of proteins, we can visualize and monitor the translation of a pathway
With multiple proprietary assays, our technology helps in identifying the molecular targets of translation modulating drugs
Multiple secondary assays use proprietary techniques to identify non-toxic compounds that specifically control the target’s translation
State of the art machine learning algorithms analyze billions of data points to identify translation modulating compounds
Proprietary image analysis algorithms run over millions of images to select images where the “translation light” has been affected
85% of known proteins have a “signature tRNA pair” that repeats with high frequency in their sequence but is relatively rare in the background human genome

A new strategy against hard and undruggable targets

Play Video

Specifically decrease or increase the production of target proteins

See the Light of Protein Translation

Translation Control Lab

Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture

Anima Lab

PSM Assays
Screening
VPN

Cloud

Translation Data
Plate Processing
Plate Analysis
Image Analysis
PSM Image Creation
Plate Design
PSM Design
Big Data Visualisation
Bio Data Center
Big Data Analysis
• Experiment Design
• Analysis Assessment
• Bio Data Analysis
The Protein Synthesis Monitoring assay uses labeled tRNA pairs that generate FRET signals to monitor ribosome activity in selected cellular system.
PSM assay in a selected cellular system is used to screen a small molecule library of compounds towards the identification of compounds which change the PSM signal.
Unbiased scores are generated from more than 90 features extracted from images.
Images captured by Operetta® are automatically uploaded to the Cloud using proprietary plate processing software.
QA measures are executed to eliminate outliers wells and cells and to identify false positives.
State of the art image analysis algorithms extract unique PSM and additional cellular features as a feed for the big data analysis.
All images are captured by Operetta®, and the clean, calculated, PSM images is generated automatically.
FRET controls, assay controls are located at specific wells in all screens, enabling strict QA algorithms.
PSM design is based on proprietary mathematical algorithms analyzing the relevant RNA code.
Powerful visual and analytical tools enable us to view the results online from various mathematical and biological angles
All biological data and results are kept in a customized industry standard bio data center.
The analysis utilizes proprietary biological big data algorithms designed for translation control modulators discovery with high level of statistical significance.

Product Pipeline

Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).

Program
Assay Development
Hit Generation
Hit to lead
Preclinical
Collagen I - Target2 Liver Fibrosis
Collagen I - Target3 Scleroderma
RSV Viral Translation Inhibitors
C-Myc Oncology / Longevity
Huntingtin Huntington's disease

Pharma Collaborations

Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

For partnering inquiries, please contact partnering@animabiotech.com.

17 Scientific Collaborations

14 Publications

Coverage

News & Events

  • BIO Investor Forum

    When: Oct. 22nd, 2019 - Oct. 23rd, 2019
    Where: San Francisco, USA

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2019 BIO Investor Forum.

    The BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2020. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings.

    Download Press Release »

    Visit the conference website »

  • BioJapan 2019

    When: Oct. 9th, 2019 - Oct. 11th, 2019
    Where: Yokohama, Japan

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2019 BioJapan World Business Forum. 

    BioJapan is Asia’s premier partnering event for the global biotechnology industry. BioJapan has been influential in furthering interaction between Japanese and global companies and advancing new business opportunities for nearly two decades. BioJapan draws in top business development, licensing, alliance management professionals, R&D personnel, and biotech company executives from around the world.

    Download Press Release »

    Visit the conference website »

  • 19th Annual Biotech in Europe Forum Hosted by Sachs Associates

    When: Sep. 25th, 2019 - Sep. 26th, 2019
    Where: Basel, Switzerland

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 19th Annual Biotech in Europe Forum hosted by Sachs Associates. Yochi Slonim, Co-founder and Chief Executive Offer of Anima Biotech, will also participate on a “Platform Technologies & Novel Therapeutics” panel.

    The Biotech in Europe Forum is the leading international stage for those interested in investing and partnering in the biotech industry. This event unites companies of all stages with leading investors, analysts, money managers and pharma licensing executives. Sachs estimates over 700 delegates and over 100 presenting companies, and 30+ pitches by seed companies.

    Download Press Release »

    Visit the conference website »